Answers are grounded in this paper and cite their sources.
Clinical review demonstrates improved overall survival in metastatic non-small cell lung cancer, highlighting the impact of biomarker-directed therapies.
Improved understanding of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Arbour et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: